Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 21:16:7-15.
doi: 10.2147/BTT.S340525. eCollection 2022.

A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon

Sally Temraz  1 , Fadi Nasr  2 , Joseph Kattan  3 , Dany Abigerges  4 , Walid Moukadem  5 , Fadi Farhat  6 , Layal Maatouk  7 , Georges Chahine  8 , Ali Shamseddine  1
Affiliations

A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon

Sally Temraz et al. Biologics. .

Abstract

Purpose: When combined with chemotherapy, bevacizumab improves progression-free survival (PFS) in metastatic colorectal cancer (mCRC). This observational trial was designed to assess the safety and efficacy of bevacizumab plus first-line chemotherapy in a real-world setting in Lebanon.

Patients and methods: A non-interventionaL multicenter study of first-LIne AVastin® (bevacizumab) in combination with chEmotherapy in patients with metastatic colorectal cancer (LLIVE) is a multicenter, prospective, Lebanon-based, observational study that enrolled mCRC patients who received first-line bevacizumab plus chemotherapy combination. The primary end point of the study was PFS. Secondary endpoints comprised the overall response rate (ORR) and the safety and tolerability of bevacizumab.

Results: A total of 196 patients were enrolled between July 2010 and August 2013. The median duration of follow-up was 11 months. Median duration of bevacizumab treatment was 4 months with FOLFOX being the chiefly chemotherapy regimen used in the first-line setting (26%). Median PFS was 8.22 months (95% confidence interval (CI): 7.005-9.443). The ORR was 50.3% (complete response 7.5%, partial response 42.8%). The most common adverse event encountered was hypertension (28%) followed by epistaxis (4.8%), diarrhea (4%), anemia (4%) and headache (4%). Grade 3/4 adverse events occurred in 15.2% of patients.

Conclusion: The trial further substantiated the efficacy and safety of bevacizumab and chemotherapy in the first-line treatment of mCRC patients in Lebanon.

Keywords: FOLFOX; XELOX; bevacizumab; metastatic colorectal cancer.

PubMed Disclaimer

Conflict of interest statement

Dr Layal Maatouk reports being an employee of Roche Lebanon SARL, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Kaplan–Meier survival curve of progression-free survival in metastatic colorectal cancer patients receiving first-line chemotherapy-bevacizumab.
Figure 2
Figure 2
Kaplan–Meier curve of progression-free survival in metastatic colorectal cancer patients with wild-type KRAS versus mutated KRAS.
See this image and copyright information in PMC

References

    1. Incidence rates by site.MOPH; 2016. https://www.moph.gov.lb/en/Pages/8/19526/national-cancer-registry. Accessed November 29, 2021.
    1. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573. doi:10.1002/cncr.24760 - DOI - PMC - PubMed
    1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-310912 - DOI - PubMed
    1. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–1676. doi:10.1200/JCO.2006.09.0928 - DOI - PubMed
    1. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103(1):21–30. doi:10.1093/jnci/djq456 - DOI - PubMed